Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daniel Alberts"'
Publikováno v:
Procedia CIRP. 94:409-413
Additive Manufacturing is on the threshold of full industrial use in various leading industries. This is due to the continuous development of machine systems regarding availability, stability, reproducibility and repeatability alongside their ever-in
Publikováno v:
Lithosphere. 2021
Wrangellia is a late Paleozoic arc terrane that occupies two distinct coastal regions of western Canada and Alaska. The Skolai arc of northern Wrangellia in south-central Alaska and Yukon has been linked to the older, adjacent Alexander terrane by sh
Autor:
Nicholas Light, Mehdi Layeghifard, Ayush Attery, Vallijah Subasri, Matthew Zatzman, Nathaniel D. Anderson, Rupal Hatkar, Sasha Blay, David Chen, Ana Novokmet, Fabio Fuligni, James Tran, Richard de Borja, Himanshi Agarwal, Larissa Waldman, Lisa M. Abegglen, Daniel Albertson, Jonathan L. Finlay, Jordan R. Hansford, Sam Behjati, Anita Villani, Moritz Gerstung, Ludmil B. Alexandrov, Gino R. Somers, Joshua D. Schiffman, Varda Rotter, David Malkin, Adam Shlien
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Li-Fraumeni syndrome (LFS) is associated with pathogenic germline TP53 variants and predisposes patients to cancer; understanding the evolution and drivers of LFS-related tumours remains crucial. Here, the authors analyse 22 LFS tumours using whole-g
Externí odkaz:
https://doaj.org/article/6313943fa94246f49c0f01dd1873ed40
Publikováno v:
Current Developments in Nutrition. 3:nzz034.P10-146
OBJECTIVES: Consumers are often constrained from procuring and consuming nutritious and safe foods by a prohibitive food environment. The Marketplace for Nutritious Foods program in peri-urban Kenya sought to mitigate this challenge by providing supp
Autor:
David D Stenehjem, Andrew W Hahn, David M Gill, Daniel Albertson, Banumathy Gowrishankar, Joseph Merriman, Archana M Agarwal, Venkata Thodima, Erik B Harrington, Trang H Au, Benjamin L Maughan, Jane Houldsworth, Sumanta K Pal, Neeraj Agarwal
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210415 (2019)
BACKGROUND:First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcom
Externí odkaz:
https://doaj.org/article/772ff832c27e41e58c93b091941976b8